Japanese pharma giant Takeda has announced plans to invest €25 million in the construction of a new facility at Grange Castle in Dublin, creating 70 new jobs.

The company plans to expand its existing footprint while also constructing a “modular cell therapy facility dedicated to manufacturing a novel stem cell therapy”.

 The project, which got support from the Ireland government, is slated to be complete in 2021 and have about 70 workers when production begins.

“We have a great team here in Ireland and are committed to continuing to put patients first through the timely manufacture and supply of high quality products from our site,” he added.

Minister of State at the Department of Enterprise and Innovation, Pat Breen, said Takeda’s investment decision was a “great win and vote of confidence in Ireland”.

IDA Ireland chief executive Martin shanahan said the decision demonstrates Takeda’s continued commitment to Ireland, adding that the State is a “globally recognised centre of excellence in life sciences due to the country’s strong regulatory track record and talent availability”.

 This is Takeda’s second investment in Ireland. Earlier in 2017, Takeda had announced a €40m investment in the construction of a stand-alone production facility for the manufacture of part of their Oncology portfolio at Grange Castle.
  

The largest pharmaceutical company in Japan, Takeda first set up operations in Ireland in 1997 manufacturing products for global markets. In 2002 Takeda chose Dublin as the location for its first active pharmaceutical ingredient (API) facility outside of Japan.